44. The solid oral dosage form of claim 42, which provides a dissolution release rate in-vitro of the drug, when measured by the USP Basket Method at 100 rpm in 700 ml Simulated Gastric Fluid (SGF) without enzymes at 37° C. of at least about 15% by weight of the drug released at 1 hour and thereafter switching to 900 ml with Phosphate Buffer at a pH of 7.5 at 37° C., of from about 25% to about 65% by weight of the drug released at 2 hours, from about 45% to about 85% by weight of the drug released at 4 hours, and at least about 60% by weight of the drug released at 8 hours.

45. The solid oral dosage form of claim 1, wherein the recovery of the drug is less than about 10% based on a syringability test whereby the dosage form is crushed and mixed with 5 mL solvent and the resultant solution is aspired with a 27 gauge needle.

46. A solid oral dosage form comprising:

a heat-labile gelling agent comprising xanthan gum;

a thermal stabilizer comprising carbomer homopolymer;

an opioid analgesic; and

a pH modifying agent comprising sodium bicarbonate;

wherein the dosage form releases at least about 85% of the drug within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml SGF at 37° C.

47. A solid oral dosage form comprising:

a heat-labile gelling agent comprising xanthan gum;

a thermal stabilizer comprising carbomer homopolymer;

an opioid analgesic comprising oxycodone, hydrocodone, a pharmaceutically acceptable salt thereof or mixtures thereof; and

a pH modifying agent comprising sodium bicarbonate to provide a pH of between about 5.5 and 8.5 to a viscous solution obtained when the dosage form is crushed and mixed with 5 mL of distilled water;

wherein the dosage form releases at least about 85% of the drug within 45 minutes as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at 50 rpm in 500 ml SGF at 37° C.

48. The solid oral dosage form of claim 46, further comprising an irritant.

49. The solid oral dosage form of claim 48, wherein the irritant comprises sodium lauryl sulfate.

50. The solid oral dosage form of claim 47, further comprising an irritant.

51. The solid oral dosage form of claim 50, wherein the irritant comprises sodium lauryl sulfate.

52. The solid oral dosage form of claim 46, wherein the recovery of the drug is less than about 10% based on a syringability test whereby the dosage form is crushed and mixed with 5 mL solvent and the resultant solution is aspired with a 27 gauge needle.

53. The solid oral dosage form of claim 47, wherein the recovery of the drug is less than about 10% based on a syringability test whereby the dosage form is crushed and mixed with 5 mL solvent and the resultant solution is aspired with a 27 gauge needle.

54. A solid oral dosage form comprising:

a heat-labile gelling agent;

a thermal stabilizer; and

a drug susceptible to abuse;

wherein the recovery of the drug is less than about 10% based on a syringability test whereby the dosage form is crushed and mixed with 5 mL solvent and the resultant solution is aspired with a 27 gauge needle.

* * * * *